Jinlong capsule combined with chemoradiotherapy for NSCLC: a Meta-analysis.
- Author:
Qiang LU
;
Jing-bin LUO
;
Yi-fan FENG
;
Qin SHE
;
Zhong-feng SHI
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
Capsules;
administration & dosage;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
radiotherapy;
Chemoradiotherapy;
Combined Modality Therapy;
Drugs, Chinese Herbal;
administration & dosage;
Humans;
Lung Neoplasms;
drug therapy;
radiotherapy
- From:
China Journal of Chinese Materia Medica
2015;40(22):4491-4496
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to evaluate the effect and safety of Jinlong capsule combined with chemotherapy or radio-therapy for non-small cell lung cancer (NSCLS) using Meta-analysis. PubMed, Embase, CNKI and Wanfang databases were all searched without language restriction, and searching time was from January 1990 to July 2015. All eligible published studies were included in this study for quality assessment and data extraction. All the data were analyzed using Revman 5.3. A total of ten studies including 736 subjects (370 in Jinlong capsule plus chemoradiotherapy and 366 in chemoradiotherapy only) were finally included in this Meta-analysis. The result of Meta analysis showed that compared with pure chemoradiotherapy group, Jinlong capsule combined with chemoradiotherapy for NSCLC could improve the patients' curative effect (OR = 1.77, 95% CI: 1.29-2.43, P < 0.05), clinical benefit rate (OR = 1.89, 95% CI: 1.22-2.91, P < 0.05), life quality improvement rate (OR = 2. 56, 95% CI: 1.61-4.05, P < 0.05), and decrease leucopenia incidence rate (OR = 0.35, 95% CI: 0. 22-0.56, P < 0.05) and gastrointestinal reaction rate (OR = 0.67, 95% CI: 0.40-1.11, P < 0.05). The pooled results showed that Jinlong capsule combined with chemoradiotherapy for NSCLC could improve the curative effect and life quality, and decrease the adverse reaction of patients.
